

## **ASX Announcement**

### **Date of AGM and Closing Date for Director Nominations**

**4 October 2022** – Race Oncology Limited (“Race”) advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting will be held at 12.00 pm AEDT on Thursday, 24 November 2022 at The Press Room, Radisson Blue Plaza Sydney, 27 O’Connell Street, Sydney, New South Wales.

An item of business at the AGM will be the re-election and appointment of Directors. In accordance with clause 14.3 of the Company’s Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a Director is Thursday, 13 October 2022.

Any nominations must be received by the Company in writing by no later than 5.00 pm AEDT on Thursday, 13 October 2022.

-ENDS

### **About Race Oncology (ASX: RAC)**

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target cancer.

The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in two clinical trials in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’ strategy.

Learn more at <https://www.raceoncology.com>

*Race encourages all investors to go paperless by registering their details with the Company’s share registry, Automic Registry Services, at [www.automicgroup.com.au](http://www.automicgroup.com.au)*

#### **Release authorised by:**

Phil Lynch, CEO/MD on behalf  
of the Race Board of Directors

[phillip.lynch@raceoncology.com](mailto:phillip.lynch@raceoncology.com)

#### **Media contact:**

Jane Lowe

+61 411 117 774

[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)